-13.7%
CTSH vs MRNA
+27.9%
-41.6%
-56.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | +0.7% | -0.5% | +0.2% |
| 7D | -9.8% | -8.2% | -1.5% | -9.4% |
| 30D | +0.1% | +125.6% | -125.5% | -6.6% |
| 3M | +13.2% | +197.1% | -183.8% | +2.8% |
| 6M | -6.2% | +148.5% | -154.7% | -13.7% |
| YTD | -28.5% | +363.3% | -391.7% | -38.4% |
| 1Y | -13.8% | +462.0% | -475.8% | -27.6% |
| All | -13.7% | +27.9% | -41.6% | -25.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling